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The demand for complex therapeutic proteins and especially monoclonal antibodies for treatment of various 
diseases has increased continuously in the last decades, prompting the continuous development of new 
processes. For the development of these cell culture processes, equipment knowledge is essential, especially 
since a process typically is scaled up and transferred numerous times in large pharmaceutical companies. The 
need for a thorough equipment understanding has been also recognized by the FDA in their PAT-publication. To 
gain such an understanding at full production scale, Boehringer Ingelheim has put tremendous effort in fully 
characterizing our multiple bioreactors at different scale across multiple sites.  Computational fluid dynamics 
(CFD) modeling is utilized which allows the evaluation of integral parameters including energy input, mixing 
time, shear forces and mass transfer coefficient (kLa). The knowledge gained through this tool has been 
instrumental in understanding the bioreactor characteristics and establish appropriate process scale up and 
transfer strategies within and across sites.  In addition, we have constructed a 15000L acrylic bioreactor model 
which provides opportunities to validate simulation results with experimental data.  For example, local behavior 
of the reactor regarding the bubble size distributions and dead zones for mixing and gassing can be visualized 
in the at-scale acrylic bioreactor. One study that was conducted is to understand mixing and mass transfer 
behavior with respect to agitation rate and superficial gas flow rate. The interactions of these parameters in 
large scale, however, were in some cases found to be counterintuitive where higher gassing and agitation did 
not consistently result in higher kLa and better mixing. Although simple modifications and standardization of 
systems can lead to more similar hydrodynamic conditions, it is difficult to make modification in existing GMP 
facility due to rigid regulations in the biopharmaceutical sector. Therefore, it is crucial to rely on engineering 
principles and CFD simulations for transfer between different sites with different bioreactor systems to give 




Figure 1 – Mixing time experiment in transparent 15000L testing facility (left) and simulation of mixing time using 
CFD (right) 
